Lupus Foundation of South Jersey
One Greentree Center
Suite 201
Marlton, NJ  08053

lupusinfo@sjlupus.org
Phone: 856-988-5444
___Fax: 856-596-8359

 


HOME

LUPUS INFO

SUPPORT

HOW TO HELP

RESEARCH


 


 

WHAT IS LUPUS

Lupus is scary; it can be life threatening, life changing and incurable. But it is also treatable, survivable and, most importantly, many aspects of the disease can be managed by you - the patient. The first step is to understand what is happening within and to your body.

Lupus means, “wolf.” Erythematosus means “redness.” In 1851, doctors coined this name for the disease because they thought the facial rash that frequently accompanies lupus looked like the bite of a wolf. Lupus can be categorized into three groups: discoid lupus erythematosus, systemic lupus erythematosus, and drug-induced systemic
lupus erythematosus.

Discoid lupus erythematosus (DLE) is characterized by a skin rash only. It occurs in about 20% of patients with systemic lupus erythematosus. The lesions are patchy, crusty, sharply defined skin plaques that may scar. These lesions are usually seen on the face or other sun-exposed areas. DLE may cause patchy, bald areas on the scalp and hypopigmentation or hyperpigmentation in older lesions. Biopsy of a lesion will usually confirm the diagnosis. Topical and intralesional corticosteroids are usually effective for localized lesions; antimalarial drugs may be needed for more generalized lesions. DLE rarely progresses to systemic
lupus erythematosus.

Systemic lupus erythematosus (SLE, or lupus) is a chronic, inflammatory, multisystem disorder of the immune system. Lupus: In SLE, the body develops antibodies that react against the person’s own normal tissue. This abnormal response leads to the many manifestations of SLE and can be very damaging. The course is unpredictable and individualized; no two patients are alike. Lupus is not contagious, infectious, or a form of cancer. It usually develops in young women of childbearing years, but many men and children also develop lupus. African Americans and Hispanics have a higher frequency of this disease than do Caucasians. SLE also appears in the first-degree relatives of lupus patients more often than it does in the general population, which indicates a strong hereditary component. However, most cases of SLE occur sporadically, indicating that both genetic and environmental factors play a role in the development of the disease.

Lupus varies greatly in severity, from mild cases requiring minimal intervention to those in which significant and potentially fatal damage occurs to vital organs such as the lungs, heart, kidney, and brain. The disease is characterized by “flares” of activity interspersed with periods of improvement or remission. A flare, or exacerbation, is increased activity of the disease process with an increase in physical manifestations and/or abnormal laboratory test values. Periods of improvement may last weeks, months, or even years. The disease tends to remit over time. Some patients never develop severe complications, and the outlook is improving for those patients who do develop severe manifestations.

Drug-induced SLE develops after the use of certain drugs and has symptoms similar to those of SLE. The characteristics of this syndrome are pleuropericardial inflammation, fever, rash, and arthritis. Serologic changes also occur. The clinical and serologic signs usually subside gradually after the offending drug is discontinued. A wide variety of drugs are implicated in this form of SLE.

Drugs with proven association
 
  • Chlorpromazine
  • Hydralazine
  • Isoniazid
  • Methyldopa
  • Procainamide


Source: National Institute of Health
 

 

 


 



What is Lupus?

Symptoms

Diagnosis

Lab Test

Cause

Treatment

Glossary

Research

Patient Information

Find a Doctor